Log In
Print
BCIQ
Print
Print this Print this
 

rindopepimut (CDX-110) (formerly PF-04948568)

Also known as: formerly ALT-110

  Manage Alerts
Collapse Summary General Information
Company Celldex Therapeutics Inc.
DescriptionVaccine targeting EGFR variant III (EGFRvIII)
Molecular Target Epidermal growth factor variant III (EGFRvIII)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationBrain cancer
Indication DetailsTreat EGFRvIII-positive recurrent glioblastoma; Treat glioblastoma; Treat glioblastoma multiforme (GBM); Treat malignant glioma; Treat newly diagnosed, EGFRvIII-positive glioblastoma following surgical resection and chemoradiation; Treat newly-diagnosed glioblastoma multiforme (GBM)
Regulatory Designation

EU - Orphan Drug (Treat glioblastoma);
EU - Orphan Drug (Treat glioblastoma multiforme (GBM))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today